Endoron Medical

Company Overview

Snapshot

Founded in July 2019 by Ronit Harpaz, Dr. Ron Karmeli, and Eyal Teichman, Endoron Medical operates with 11–50 employees. The company has raised $15 million across two funding rounds from two investors. In July 2024, Endoron Medical secured Series A funding, with Sofinnova Partners participating.

Business overview

Endoron Medical develops a catheter-based endovascular suturing device, Aortoseal, designed to provide a long-lasting sealing and fixation solution for endografts in abdominal aortic aneurysm patients. The technology mimics hand-sewn suturing techniques from open surgery, distributing staples circumferentially around the aorta to create leak and migration-free anastomosis. Aortoseal aims to reduce complications and reinterventions by securely holding the stent graft in place, enabling endograft procedures across various anatomies. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving the healthcare industry.

Strategic signal

Endoron Medical's successful Series A funding round in July 2024, with participation from Sofinnova Partners, signals strong investor confidence in its Aortoseal technology. This capital infusion is crucial for advancing the company's catheter-based endovascular suturing device, indicating a positive trajectory for its clinical development and market entry in the medical device sector.

Company Intelligence Q&A

What is Endoron Medical's core technology?

Endoron Medical's core technology is Aortoseal, a catheter-based endovascular suturing device designed to provide a long-lasting sealing and fixation solution for endografts in abdominal aortic aneurysm patients.

When was Endoron Medical founded and by whom?

Endoron Medical was founded in July 2019 by Ronit Harpaz, Dr. Ron Karmeli, and Eyal Teichman.

What was a significant recent funding event for Endoron Medical?

In July 2024, Endoron Medical raised Series A funding, with Sofinnova Partners participating in the round.

Which investor participated in Endoron Medical's Seed round?

In December 2021, Sofinnova Partners participated in Endoron Medical's Seed funding round.

What problem does Endoron Medical's Aortoseal device address?

The Aortoseal device addresses the need for a reliable, long-lasting sealing and fixation solution for endografts in abdominal aortic aneurysm patients, aiming to reduce complications and reinterventions associated with current endovascular aneurysm repair procedures.